Trifluoroacetic Acid
Trifluoroacetic acid is a corrosive organofluorine compound that is structurally analogous to, but stronger than, acetic acid. Available in various quantities and reagent grades, it is used in NMR spectroscopy, mass spectrometry, organic synthesis, etc.
Almost 100,000-fold more acidic than acetic acid, TFA is widely used in organic chemistry. TFA is used as a reagent in organic synthesis because of its properties: volatility, organic solvent solubility, and acidic strength. It is less oxidizing than sulfuric acid and is more readily available in its anhydrous form than some other acids . Other features include:
- Used in acid-catalyzed reactions, especially peptide synthesis (to cleave esters)
- Dissolves protein when mixed with liquid SO2
- Removes t-butyl derived side-chain protecting groups in Fmoc peptide synthesis
- Can remove the t-butoxycarbonyl protecting group in organic synthesis
- At low concentrations, acts as an ion-pairing agent for peptides and small proteins in organic compound liquid chromatography
- For acid-stable materials, can be a solvent for NMR spectroscopy
- Acts as a calibrant in mass spectrometry
- Used to produce trifluoroacetate salts
- An ingredient in adhesives, sealants, paints, and coatings
When TFA combines with bases and metals, especially light metals, a strong exothermic reaction occurs. When mixed with lithium aluminum hydride (LAH), the reaction is explosive.
Although nonflammable, TFA is corrosive to skin, eyes, and mucous membranes and requires careful use and handling. It is harmful when inhaled, causes severe skin burns and eye damage, and is toxic to aquatic organisms at even low concentrations.
TFA is also a product of the metabolic breakdown of the anesthetic agent halothane. It is the suspected cause of halothane-induced hepatitis.
Apexbio Technology LLC FSLLRY-NH2 TFA 245329-02-6 (free base) 1mg
FSLLRY-NH2 TFA is a synthetic peptide antagonist targeting protease-activated receptor 2 (PAR-2) It is designed to block PAR-2 activation thereby inhibiting intracellular signaling cascades such as calcium mobilization and MAP kinase activation that underlie inflammatory responses nociceptive transmission and immune modulation FSLLRY-NH2 TFA exerts its biological activity primarily through competitive binding to PAR-2 preventing receptor activation and downstream signaling events Based on these pharmacological properties FSLLRY-NH2 TFA holds research potential in the study of inflammation-associated disorders and pain pathways
Chem-Impex International, Inc. Trifluoroacetic acid | 76-05-1 | MFCD00004169 | 1KG
Trifluoroacetic acid, 76-05-1, MFCD00004169, 1KG
Medchemexpress LLC Batifiban TFA | 00-00-0 | 99.6% | 817.94 g/mol | C34H47N11O9S2 · xC2HF3O2 | 5 MG
Batifiban TFA is a cyclic peptide antagonist of platelet glycoprotein IIb/IIIa that inhibits platelet aggregation by blocking ligand binding such as vitronectin. Supplied as the trifluoroacetate (TFA) salt for research use, it is provided as a high-purity powder suitable for in vitro biochemical and cellular assays.
- Antagonizes platelet glycoprotein IIb/IIIa to inhibit aggregation.
- Blocks vitronectin binding to integrin receptors.
- Supplied as trifluoroacetate (TFA) salt for stability.
- High purity (~99.6%) suitable for biochemical assays.
- Available in small research pack sizes, including 5 mg.
- Store sealed, away from moisture and light; long-term storage at -80°C.
Apexbio Technology LLC FSLLRY-NH2 TFA 245329-02-6 (free base) 25mg
FSLLRY-NH2 TFA is a synthetic peptide antagonist targeting protease-activated receptor 2 (PAR-2) It is designed to block PAR-2 activation thereby inhibiting intracellular signaling cascades such as calcium mobilization and MAP kinase activation that underlie inflammatory responses nociceptive transmission and immune modulation FSLLRY-NH2 TFA exerts its biological activity primarily through competitive binding to PAR-2 preventing receptor activation and downstream signaling events Based on these pharmacological properties FSLLRY-NH2 TFA holds research potential in the study of inflammation-associated disorders and pain pathways